DalCor’s Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule — Dalcetrapib Studied in Genetically Distinct Patients with Acute Coronary Syndrome
DalCor Pharmaceuticals today announced it is ahead of the enrollment schedule with the randomization of over 1,000 patients of the expected 5,000 patients planned for the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene.
